Search Results - camilo+rojas

5 Results

Sort By:

Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors

Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...

Published: 3/14/2025 | Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas

Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules

Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection

Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...

Published: 3/13/2025 | Inventor(s): Norman Haughey, Barbara Slusher, Camilo Rojas

Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > HIV

Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases

Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Discovery of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases

Unmet NeedAlzheimer’s disease (AD) is the most common form of dementia, affecting approximately 5.7 million people in the United States in 2018. Yet, no cure exists for AD, and AD therapeutics presently on the market fail to treat the disease’s underlying causes. Recent studies in mice reveal that exosomes released from glial cells contribute to the...

Published: 3/14/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Norman Haughey, Marc Ferrer, Xin Hu

Keywords(s): Antagonists/Inhibitors, Cancers, CNS and Neurological Disorders, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules

Quantitation of GCPII Enzymatic Activity in Human Skin Biopsies as a Clinical Biomarker

We have identified a unique tissue preparation and enzymatic assay conditions to quatitatively monitor glutamate carboxypeptidase II (GCPII) activity in human skin biopsy samples. This assay can be utilzed as a phanacodynamic (PD) marker in the clinical development of novel GCPII inhibitors. This new assay is a significant improvement over GCPII biomarker...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Marigo Stathis, Michael Polydefkis

Keywords(s): Assay, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Multiple CNS Indications, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities